TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15974555
Drug: Nurse-administered 6-month
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered 6-month telephonic case management intervention (Asthma Treatment Awareness Project)
Study: 10503585
Drug: Lamotrigine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamotrigine (25 mg for 2 weeks, 50 mg for 2 weeks, and 100 mg for 4 weeks)
Study: 10503585
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets (taken once daily)
Study: 8941876
Drug: Low-dose IL-2
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose IL-2 (1.2 x 10(6) IU/m2)
Study: 8941876
Drug: High-dose IL-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose IL-2 (1.2 x 10(7) IU/m2)
Study: 2010875
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis treatment including cranial irradiation and intrathecal methotrexate
Study: 2010875
Drug: CNS prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS prophylaxis treatment including only intrathecal methotrexate and intermediate dose infusions of methotrexate
Study: 7023527
Drug: Sustained-release aminophylline
Normalized name: aminophylline Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release aminophylline
Study: 19957798
Drug: Low-dose Methotrexate
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose Methotrexate + Leflunomide (MTX + LEF)
Study: 17922442
Drug: Multifactorial therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifactorial therapeutic approach (glycemic control, antihypertensive therapy, RAAS inhibition, statins, aspirin)
Study: 17922442
Drug: Optimal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal blood pressure levels < 130/80 mmHg for proteinuria < 1 g/day
Study: 17922442
Drug: Optimal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal blood pressure levels < 120/75 mmHg for proteinuria ≥ 1 g/day
Study: 15781600
Drug: Psycho-educational program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-educational program (10 weekly sessions)
Study: 11981724
Drug: Amoxicillin/clavulanate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (90 mg/kg per day)
Study: 9609359
Drug: alpha‐tocopherol nicotinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐tocopherol nicotinate 300 mg tds after meals for 3 months
Study: 8553592
Drug: Spirapril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirapril monotherapy
Study: 2797894
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g of cefamandole at induction of anaesthesia and 750 mg every six hours during 24 hours after surgery
Study: 2797894
Drug: Single injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 1.5 g of cefamandole at induction of anaesthesia
Study: 381229
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg ascorbic acid daily
Study: 381229
Drug: 4000 mg
Normalized name: talc 4000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4000 mg ascorbic acid daily
Study: 30069600
Drug: Dydrogesterone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dydrogesterone (20 mg/day) plus HMG (150 or 225 IU)
Study: 24430001
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen
Study: 27300114
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (after 48 months of treatment)
Study: 25112084
Drug: Acupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture at Baihui (GV 20), Sishencong (EX‐HN 1), Neiguan (PC 6), Zusanli (ST 36), and Hegu (LI 4) for 20 minutes, twice a week for 10 treatments.
Study: 25112084
Drug: Delayed acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed acupuncture (no treatment during observation stage).
Study: 22192643
Drug: Valsartan/Amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine 80/5 mg (single dose)
Study: 22192643
Drug: Valsartan/Amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine 80/5 mg (multiple dose, once-daily for 9 days)
Study: 22192643
Drug: Valsartan/Amlodipine 80/5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/Amlodipine 80/5 mg (single and multiple doses)
Study: 11793614
Drug: cilomilast 15
Normalized name: CILOMILAST
DrugBank: Cilomilast (DB03849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: cilomilast 15 mg twice daily
Study: 9745987
Drug: Melatonin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (6 mg), administered 2 hr before habitual bedtime
Study: 2467328
Drug: Low-fibre diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-fibre diet during and after first cycle of cisplatin and vinblastine chemotherapy (Group 1)
Study: 29722943
Drug: Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Undecanoate Pills (TUP)
Study: 29722943
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (maintaining glucose- and lipid-reducing therapies)
Study: 26070917
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg orally once daily
Study: 16957145
Drug: No adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: No adjuvant chemotherapy (Control)
Study: 24910102
Drug: Ketamine 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.4 mg/kg
Study: 12859309
Drug: Lidocaine 2.5
Normalized name: LIDOCAINE 2.5% OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2.5 mg/kg
Study: 16159930
Drug: Daily GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily GH (n = 53)
Study: 16159930
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 31)
Study: 1779084
Drug: Active based
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active based cream F14001
Study: 1779084
Drug: Placebo non-active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo non-active based cream
Study: 6122463
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg oxprenolol
Study: 6111331
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg sotalol
Study: 31122797
Drug: Maternal triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal triple antiretroviral treatment throughout both ante‐partum and post‐partum phases
Study: 31122797
Drug: Maternal non-adherence
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal non-adherence to triple antiretroviral treatment
Study: 31122797
Drug: Maternal triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal triple antiretroviral treatment
Study: 8070935
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B alone (0.5 mg/kg/day; n = 14)
Study: 8070935
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.5 mg/kg/day) plus 5-flucytosine (150 mg/kg/day; n = 14)
Study: 31561960
Drug: Atorvastatin (0.125-0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (0.125-0.75 mg/kg/day)
Study: 31561960
Drug: Atorvastatin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (0.75 mg/kg/day)
Study: 23853246
Drug: Ixabepilone 40
Normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ixabepilone 40 mg/m2 (3‐hour infusion) every 3 weeks for four cycles
Study: 23853246
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel 80 mg/m2 (1‐hour infusion) for 12 weeks
Study: 18290863
Drug: Supportive psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive psychotherapy treatment
Study: 16817265
Drug: Phased whole
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phased whole acupuncture therapy
Study: 12923621
Drug: Enteral glutamine
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral glutamine (20 g/l)
Study: 12923621
Drug: Control (isonitrogenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (isonitrogenous and isojoulic solution)
Study: 8237969
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (3 g of calcium carbonate daily)
Study: 3815460
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte interferon (100 micrograms daily for nine weeks)
Study: 21083771
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 40 puffs of 0.2 mg salbutamol
Study: 21083771
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two placebo tablets)
Study: 18797274
Drug: New anticholinergic
Approvals — FDA: no, EMA: no, PMDA: no
Description: New anticholinergic medications
Study: 15983464
Drug: Sequential Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential Epidural Bolus (SEB) technique
Study: 15983464
Drug: Continuous Epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Epidural Infusion (CEI) technique
Study: 12209503
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg tacrolimus
Study: 10645753
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg tacrolimus
Study: 12209503
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tacrolimus
Study: 7476742
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg oral tablet on admission, followed by 50 mg infusion in 250 ml dextrose 5% over 30 minutes)
Study: 7476742
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg oral tablet and 100 mg infusion in 250 ml dextrose 5% over 30 minutes)
Study: 1683545
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of activated charcoal administered simultaneously with 400 mg amiodarone
Study: 1683545
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g of activated charcoal administered 1.5 hours after 400 mg amiodarone
Study: 1683545
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 400 mg amiodarone and water only
Study: 20382428
Drug: Topical nonsteroidal
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nonsteroidal anti-inflammatory drug (ketorolac)
Study: 20382428
Drug: Topical steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroid (fluorometholone)
Study: 14646439
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine gel (Instillagel) intraurethrally for approximately 15 min
Study: 14646439
Drug: Water-soluble gel
Normalized name: WATER SOLUBLE BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-soluble gel (Aquagel) smeared around the scope and external urethral meatus
Study: 15531005
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 mg once daily
Study: 28134604
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no buccal grafting)
Study: 24998121
Drug: Chronic warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic warfarin therapy
Study: 19233692
Drug: Sequential deferiprone-deferoxamine
Normalized name: Deferiprone
DrugBank: Deferiprone (DB08826)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sequential deferiprone-deferoxamine (DFP-DFO)
Study: 17595355
Drug: Pioglitazone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (30 mg q.d. for 12 weeks followed by 45 mg q.d. for another 12 weeks)
Study: 17595355
Drug: Rosiglitazone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone (4 mg q.d. followed by 4 mg b.i.d. for the same intervals)
Study: 1423953
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units urokinase i.v. over 90 minutes plus intravenous heparin (group A)
Study: 1423953
Drug: 3 million
Normalized name: INTERFERON GAMMA-1B 3 MILLION UNT/0.5ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 million units urokinase i.v. plus 325 mg aspirin p.o. daily (group B)
Study: 1423953
Drug: Placebo thrombolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo thrombolytic infusion plus full‐dose heparin (group C)
Study: 27136622
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg weekly (ew)
Study: 20819563
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg of body weight, daily) for continuous 7 days
Study: 17178185
Drug: Placebo injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injection (30 patients)
Study: 12672860
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg daily for 28 weeks
Study: 8617705
Drug: Sertraline 100
Normalized name: sertraline 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 100 micrograms plus atenolol 50 mg
Study: 8617705
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus atenolol 50 mg
Study: 3888388
Drug: vindesine plus
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vindesine plus cisplatin (vindesine 3 mg/m2, cisplatin 120 mg/m2)
Study: 3888388
Drug: vinblastine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: vinblastine plus cisplatin (vinblastine 6 mg/m2, cisplatin 120 mg/m2)
Study: 30621836
Drug: CPAP therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPAP therapy with symptoms
Study: 30249632
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of myo-inositol powder, twice daily until delivery
Study: 30249632
Drug: Placebo, twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, twice daily until delivery
Study: 27487640
Drug: Rectal acetaminophen
Normalized name: acetaminophen Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal acetaminophen
Study: 18082485
Drug: 1 daily
Normalized name: PAXLOVID 150MGX2/100MGX1 DAILY PKT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 daily injection of insulin glargine (titrated to achieve fasting plasma glucose < or = 5.3 mmol/L)
Study: 18082485
Drug: omega‐3‐acid ethyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega‐3‐acid ethyl esters 90 (1 g consisting of EPA 465 mg and DHA 375 mg)
Study: 11726736
Drug: Melatonin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (20 mg orally in two doses of 10 mg each, with a 1-h interval)
Study: 9323286
Drug: Single-dose and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose and divided-dose prednisolone
Study: 8517508
Drug: Background infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Background infusion (BI) at 1 mg/hr with patient-controlled analgesia (PCA)
Study: 3705683
Drug: Diltiazem (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (3 X 60 mg daily)
Study: 11199945
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus pindolol
Study: 24731672
Drug: Exenatide (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (2 mg subcutaneous injection once weekly)
Study: 24731672
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (titrated to target once daily)
Study: 16006907
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (CBJ) 1 liter daily
Study: 7016800
Drug: EMD 21
Normalized name: Emdisterone
DrugBank: Drostanolone propionate (DB14655)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMD 21 657 (3 X 400 mg/day p.o.) + maprotiline (75 mg/day p.o.)
Study: 7016800
Drug: maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: maprotiline (75 mg/day p.o.)
Study: 12032024
Drug: Dextromethorphan (DM)
Normalized name: Dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dextromethorphan (DM) 90 mg
Study: 6711779
Drug: Cimetidine 10
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 10 mg/kg orally given 120-180 minutes pre-operatively
Study: 6711779
Drug: Cimetidine 10
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 10 mg/kg orally
Study: 27815799
Drug: Conjugated linoleic
Normalized name: CONJUGATED LINOLEIC ACID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjugated linoleic acid (CLA) - 2 daily 1.25 g capsules (totaling about 2 g of CLA in glycerinated form)
Study: 27815799
Drug: Placebo -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 daily 1.25 g capsules containing sunflower oil with high oleic acid
Study: 15756252
Drug: Capecitabine 1150
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1150 mg m‐2 twice daily with irinotecan 250 mg m‐2
Study: 15756252
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg m‐2 with irinotecan 250 mg m‐2
Study: 15756252
Drug: Capecitabine and
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine and irinotecan combination therapy
Study: 12540205
Drug: Length-normalized pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Length-normalized pulse photoplethysmography (D/l)
Study: 9681402
Drug: 0.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 g/kg HBOC‐201
Study: 7988131
Drug: Sucralfate (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (2 g every 8 hrs)
Study: 7988131
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL of sterile water every 8 hrs)
Study: 2521989
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (lower doses)
Study: 4567765
Drug: Marijuana (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana (dosage and smoking procedure standardized)
Study: 4567765
Drug: Placebo (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (dosage and smoking procedure standardized)
Study: 30169915
Drug: OIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PI (30% weekly plus 5% daily increments)
Study: 30169915
Drug: OIT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: OIT with pasteurized egg white (PEW), target dose 3.3 g PEW proteins, buildup pattern PII (30% weekly increments)
Study: 29619533
Drug: CBD (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD (600 mg/day)
Study: 26706022
Drug: Probiotic supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplements (n = 20)
Study: 17509869
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (group EA) with a 7‐mL epidural bolus 0.1% bupivacaine containing fentanyl 50 mug (n=20)
Study: 16450805
Drug: Techniques or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Techniques or adjuvant medical treatment to reduce clot expansion and rebleeding
Study: 9700469
Drug: Triglyceride emulsion
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride emulsion infusion (Lipid infusion study)
Study: 9700469
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Saline infusion study)
Study: 7623616
Drug: CI-979 (0.5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-979 (0.5-mg q6h, 1-mg q12h, 1-mg q6h, 2-mg q12h, 2-mg q6h, 2.5-mg q6h, and 3-mg q6h)
Study: 2569324
Drug: Conventional (C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional (C) propranolol 160 mg
Study: 2569324
Drug: Long acting
Normalized name: Long Acting Nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long acting (LA) propranolol 160 mg
Study: 7176839
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment in patients with CAH (total group)
Study: 7176839
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment in patients with cirrhosis and CAH (Group I A)
Study: 7176839
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment in patients with probably cirrhosis and CAH (Group I B)
Study: 7176839
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment in patients compatible with but not diagnostic for cirrhosis and CAH (Group I C)
Study: 7176839
Drug: Prednisone treatment
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone treatment in patients without CAH (Group II A + B + C)